The increased drug load enabled by the nanoformed particles also allows smaller implants with sustained release properties to be developed.
Cullgen will have the option during the initial stages of clinical development to participate equally in the costs, profits and losses
Laurus will also provide funding for the clinical trials and will launch these products in India and emerging markets
Convergent action on AMR identified as an important area of intervention
Samsung Biologics will provide Pfizer with additional capacity for large-scale manufacturing for a multi-product biosimilars portfolio
Lantern is receiving an exclusive and worldwide option to license intellectual property from Bielefeld University related to the collaboration and IP generated from the collaboration
Health Secretary highlights the need for capacity building programmes for Medical Officers to tackle Non Communicable Diseases at the primary level
Construction will begin this year with the new capacity anticipated by 2025
Acuitas Therapeutics' LNP technology will support Bayer’s in vivo gene editing and protein replacement programs with the goal of specifically delivering RNA payloads to the desired target organ, the liver.
The collaboration focuses on the development and sharing of Standard Quality and Regulatory Documentation (StaQRD), a standard guide for the electronic transfer of information
Subscribe To Our Newsletter & Stay Updated
